Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of zigakibart in adults with primary IgA nephropathy
2024-519638-22-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
Phase 3, open-label, single-arm trial of zigakibart in IgA nephropathy (IgAN), sponsored by Novartis. Primary endpoints: Treatment-emergent adverse events and Adverse events of special interest. Planned start Aug 2026; status: authorised.
02
Drugs
zigakibart
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2024-519638-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519638-22-00.